Alternatives to TeleDocs360

Bodybuilding Health+ does the disclosure part better than most of this market and the branding part more loosely. It names four compounding pharmacies outright with phone numbers, and it names two lead physicians with their NPI numbers — both of whom check out as active MDs in the federal registry. Pricing is flat at every dose and public before any intake: $179 a month for compounded semaglutide and $209 for tirzepatide, dropping to $139 and $159 only if you buy a year up front. The looser part is the name. The operator is Dynamo Group LLC of Boca Raton, not Bodybuilding.com, and the 'trusted by millions since 1999' line on the page is the licensor's heritage rather than the clinic's. It's compounded-only, so there's no FDA-approved Wegovy or Zepbound route, the bundle discounts come with no published refund terms, and a prominent '4.8 (200+ reviews)' badge sits above a Trustpilot widget I couldn't verify because Trustpilot blocks automated checks.

The async, needle-optional value play: oral or injectable semaglutide and tirzepatide from a low starting price, no video visit, ~3 days to a script — listed with its February 2026 FDA warning letter in plain view.

No video visit and no membership fee — semaglutide from $117.96/mo, tirzepatide from $178.98/mo — but Trava's own pages currently disagree with each other on its clinical-partner name and its cheapest semaglutide price.

FDA warning letter #721479 (Feb. 2026), which names joinbliv.com. An explicitly no-video-visit, fully async intake — as low as $116/mo semaglutide, $199/mo tirzepatide — with CareCredit and Klarna pay-later options, though state coverage isn't published.

Rehydra+ Wellness is the one provider added here that charges more as your dose goes up, and it is unusually open about it: its storefront publishes a complete dose-by-duration matrix, so you can see before signing up that compounded semaglutide runs $149 for four weeks at the 0.25 mg starting dose and $289 at 2.5 mg, while tirzepatide runs $219 at 2.5 mg and $649 at 15 mg. That transparency is genuinely useful, and it also means the entry price is the least representative number on the page — if you titrate to an effective dose, your cost roughly doubles. Six-month tier plans bring the per-month figure down to $119 and $169, but they are six-month commitments rather than rolling plans. It is a small San Antonio operation founded in 2023, offering a free 15-minute telehealth call and free shipping. The two real gaps: it names no pharmacy and no individual clinician, and its own pages disagree on coverage — the weight-loss landing page says 19 states and lists 19, while the homepage says 20.

Coby publishes its whole dose-scaling ladder up front, which is rarer than it should be: read live on 2026-08-26, compounded semaglutide runs $159, $199, $229, then $249 and holds there, and tirzepatide runs $239, $299, $329, $379, then $439. Every rung is unchanged since early August. It also answers the two questions most sellers dodge. On video, its FAQ says outright that unless your state requires one, no video visit is needed and your provider reviews everything online. On coverage, it names the four states it does not reach — Arkansas, Louisiana, Mississippi and New Mexico — instead of staying vague. Two things go the other way. Coby's month is four weeks by its own arithmetic, since it sells a three-month bundle as twelve weeks and a six-month bundle as twenty-four, so a year is thirteen bills rather than twelve. And changing your mind costs money: canceling before the prescription reaches the pharmacy deducts a $50 non-refundable visit and clinical fee from the refund, and once it has been sent, the order cannot be changed at all.

The habit-plus-medication route: Noom bolts a prescriber onto its behavior-change app, runs mostly async, and will chase brand-name coverage through insurance — but it won't tell you which molecule you're getting or your true quarterly total up front.

$199/mo semaglutide, $299/mo tirzepatide, three named co-founders, no contracts, a claimed ~24-hour NP review, and no live video visit described anywhere in the flow — undercut by an on-site 'FDA Approved' badge that overstates what's actually true about compounded GLP-1s, plus no pharmacy named and no state list disclosed. That combination — real speed and a named founding team, next to an overstated regulatory badge and thin disclosure elsewhere — is why Spry lands in the middle of the pack rather than near the top on this site's Rx-Readiness scorecard.

FDA warning letter #721449 (Feb. 2026), which names goodgirlrx.com. No required video visit and both molecules across six formats — injectable, microdose, oral dissolving tablets — all-inclusive from $134/mo, from a brand barely a year old.